July 30 – July 31, 2020
Innovations in Cancer Prevention and Research Conference
Extending CPRIT’s Impact to Texas Communities

James P. Allison, PhD

James P. Allison, PhD

Chair and Regental Professor, Department of Immunology
The University of Texas M.D. Anderson Cancer Center

2018 Nobel Laureate in Medicine and Physiology
Executive Director, Immunotherapy Platform
CPRIT Scholar

Jim Allison, who received the 2018 Nobel Prize for Physiology or Medicine, has spent a distinguished career studying the regulation of T cell responses and pioneering new strategies for cancer immunotherapy. Among his most notable discoveries are the determination of the T cell receptor structure and that CD28 is the major costimulatory molecule that allows full activation of naïve T cells and prevents anergy in T cell clones.

His lab resolved a major controversy by demonstrating that CTLA-4 inhibits T-cell activation by opposing CD28-mediated costimulation and that blockade of CTLA-4 could enhance T cell responses, leading to tumor rejection in animal models. He proposed that blockade of immune checkpoints such as CTLA-4 might be a powerful strategy for therapy of many cancer types, and conducted preclinical experiments showing its potential. These seminal findings established the field of immune checkpoint blockade therapy for cancer, which earned him the Nobel Prize.

James P. Allison, PhD's Sessions


session speaker/presenter
session moderator
Thursday, July 30, 2020
Immune Checkpoint Blockade in Cancer Therapy: Historical Perspective, New Opportunities, and Prospects for Cures
James P. Allison, PhD

8:30 AM TBD

Copyright © 2020 Cancer Prevention and Research Institute of Texas